Improvement of walking ability, balance and coordination in patients with multiple sclerosis under PR Fampridine therapy

Recruiting

• Conditions: G35; Multiple sclerosis

• Registration Number: DRKS00009228
• Lead Sponsor: Biogen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-08-25
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Clinical indication for a therapy with Fampridine according to german SmPC

Exclusion Criteria

Contra- indication for a therapy with Fampridine according to german SmPC

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patients who are treated with fampridine during routine clinical treatment take part in an electronic walking test prior to and following fampridine administration. During this walking test, patients walk back and forth a distance of 25-ft for a maximal period of six minutes.<br><br>Primary Endpoint: Walking distance covered on the walking test, prior to and during treatment with fampridine. Respective measurements occur during routine clinical treatement on a quarterly (year) basis.

Secondary Outcome Measures

Name	Time	Method
Secondary Endpoint:<br><br>Speed during the covering of curves in the 25-ft walk. Additionally: Measurement of Fatigue by means of the self-report measure Würzburger Erschöpfungsinventar bei Multipler Sklerose (WEIMUS), administered on the same occasions during which the walking test is implemented.